- Baird Medical’s ceramic thyroid ablation needle receives Class III certification from China’s NMPA, boasting an advanced design utilizing rare earth ceramic materials for improved precision and reliability in treating thyroid nodules. This innovative technology, designed to distribute energy uniformly during microwave ablation treatments, promises to enhance patient treatment experiences and potentially save lives by optimizing heating efficiency and minimizing the risk of breakage.
- University of Birmingham researchers are developing a new ‘lollipop’ diagnostic for mouth cancer using a smart hydrogel, funded by Cancer Research UK and the Engineering and Physical Sciences Research Council. The biocompatible hydrogel, created by Dr. Ruchi Gupta and colleagues, concentrates and labels proteins with a fluorescent marker in a single step, offering a promising alternative to current invasive and time-consuming diagnostic methods.
- Neurava, based in Indianapolis, raises $2.3 million in an oversubscribed seed financing round for its novel wearable device aimed at mitigating the risk of sudden unexpected death in epilepsy (SUDEP). The device monitors seizures, cardiorespiratory dysfunctions, and the risk of SUDEP, enabling life-saving intervention, with plans to complete pivotal usability studies, set up manufacturing partners, and seek FDA clearance.
- Paragonix Technologies launches its BAROguard Donor Lung Preservation System nationwide after a successful limited market release, providing transplant centers and Organ Procurement Organizations with real-time data on the condition of donor lungs during transport. Equipped with active airway management and built-in tracking, the device aims to revolutionize lung preservation, with clinical experts praising its potential to increase the availability of quality donor lungs for transplantation, as it is showcased at the 44th ISHLT Annual Meeting and Scientific Sessions in Prague, Czech Republic.
- Johnson & Johnson confirms its acquisition of Shockwave Medical for $13.1 billion, dismissing rumors that had surfaced earlier. The move is expected to bolster J&J’s presence in the cardiovascular intervention market, following previous acquisitions in heart recovery and atrial fibrillation technology, with plans to close the deal by mid-2024.
Sources:
- https://www.medicaldevice-network.com/news/baird-class-iii-needle/
- https://www.med-technews.com/news/latest-medtech-news/university-of-birmingham-scientists-using-novel-hydrogel-to-create-%E2%80%98lollipops%27-for-mouth-cancer-diagnostic/
- https://www.massdevice.com/neurava-raises-2m-epilepsy-monitoring-tech/
- https://www.medicaldesigndevelopment.com/topics/equipment/news/22892227/paragonix-begins-full-commercial-launch-for-donor-lung-preservation-system
https://www.mddionline.com/ma/j-j-puts-the-rumors-to-bed-moves-to-acquire-shockwave
ThinkMedTek 
Leave a comment